TELA Bio, Inc. (TELA)

TELA Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	58.45	41.42	29.46	18.21	15.45
Revenue Growth (YoY)	41.13%	40.58%	61.77%	17.91%	86.68%
Cost of Revenue	18.34	14.37	10.65	6.98	6.17
Gross Profit	40.11	27.04	18.81	11.23	9.27
Selling, General & Admin	74.57	57.11	41.52	32.25	24.28
Research & Development	9.62	8.94	6.74	4.26	4.15
Operating Expenses	84.19	66.05	48.26	36.51	28.43
Operating Income	-44.08	-39.01	-29.45	-25.28	-19.16
Interest Expense / Income	5.22	4.05	3.6	3.56	3.61
Other Expense / Income	-2.63	1.24	0.23	-0.05	-0.35
Pretax Income	-46.66	-44.3	-33.28	-28.79	-22.43
Net Income	-46.66	-44.3	-33.28	-28.79	-22.43
Preferred Dividends	0	0	0	0	7.78
Net Income Common	-46.66	-44.3	-33.28	-28.79	-30.21
Shares Outstanding (Basic)	23	16	14	13	2
Shares Outstanding (Diluted)	23	16	14	13	2
Shares Change	40.58%	12.40%	11.90%	632.24%	498.81%
EPS (Basic)	-2.04	-2.72	-2.30	-2.23	-17.10
EPS (Diluted)	-2.04	-2.72	-2.30	-2.23	-17.10
Free Cash Flow	-41.46	-41.62	-31.06	-24.62	-25.72
Free Cash Flow Per Share	-1.81	-2.56	-2.15	-1.90	-14.56
Gross Margin	68.62%	65.30%	63.85%	61.68%	60.03%
Operating Margin	-75.40%	-94.18%	-99.96%	-138.77%	-124.06%
Profit Margin	-79.83%	-106.95%	-112.94%	-158.10%	-195.57%
Free Cash Flow Margin	-70.92%	-100.49%	-105.42%	-135.19%	-166.52%
EBITDA	-40.63	-39.06	-29.14	-24.71	-18.23
EBITDA Margin	-69.51%	-94.30%	-98.92%	-135.64%	-118.05%
Depreciation & Amortization	0.81	1.19	0.54	0.53	0.58
EBIT	-41.44	-40.25	-29.68	-25.23	-18.82
EBIT Margin	-70.90%	-97.17%	-100.73%	-138.53%	-121.82%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).